Interojo Inc. (KOSDAQ:119610)
15,540
-80 (-0.51%)
Nov 20, 2025, 3:30 PM KST
Interojo Revenue
Interojo had revenue of 31.34B KRW in the quarter ending June 30, 2025, with 17.61% growth. This brings the company's revenue in the last twelve months to 110.02B, down -4.65% year-over-year. In the year 2024, Interojo had annual revenue of 115.84B, down -2.90%.
Revenue (ttm)
110.02B
Revenue Growth
-4.65%
P/S Ratio
1.52
Revenue / Employee
156.51M
Employees
703
Market Cap
167.59B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 115.84B | -3.46B | -2.90% |
| Dec 31, 2023 | 119.30B | 1.48B | 1.25% |
| Dec 31, 2022 | 117.82B | 10.29B | 9.57% |
| Dec 31, 2021 | 107.53B | 19.33B | 21.92% |
| Dec 31, 2020 | 88.20B | -4.37B | -4.72% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.03T |
| Celltrion | 3.75T |
| Yuhan | 2.17T |
| Hanmi Pharm. | 1.50T |
| SK Biopharmaceuticals | 620.28B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |
| LigaChem Biosciences | 148.28B |